Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.76 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5817555 | 0.87 | P2RX7 (1.00) | P2RX7TRPA1SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL5815997 | 0.87 | P2RX7 (0.74) | P2RX7TRPA1SIGMAR1KCNN4HSD11B1 | |
| SCHEMBL6357093 | 0.86 | P2RX7 (0.73) | P2RX7TRPA1SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL6361602 | 0.83 | P2RX7 (0.70) | P2RX7TRPA1SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL6358726 | 0.82 | P2RX7 (0.61) | P2RX7KCNN4HSD11B1 | |
| SCHEMBL6361632 | 0.81 | P2RX7 (0.63) | P2RX7TRPA1SIGMAR1 | |
| SCHEMBL6354523 | 0.81 | P2RX7 (0.82) | P2RX7TRPA1SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL5816280 | 0.78 | P2RX7 (1.00) | P2RX7TRPA1SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL6358683 | 0.78 | P2RX7 (0.80) | P2RX7TRPA1SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL6361640 | 0.78 | P2RX7 (0.82) | P2RX7KCNN4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | P2RX7 448/4885TRPA1 708/4885SIGMAR1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.